Valuation: StemCell Institute Inc.

Market Cap 7.77B 47.75M 41.88M 38.67M 35.73M 67.72M 4.57B 69.08M 465M 181M 2.24B 179M 175M P/E 2026
49.6x
P/E 2027 * 69.5x
Enterprise Value 7.77B 47.75M 41.88M 38.67M 35.73M 67.72M 4.57B 69.08M 465M 181M 2.24B 179M 175M EV / Sales 2026
2.79x
EV / Sales 2027 * 2.51x
Free-Float
23.41%
Yield 2026 *
-
Yield 2027 * -
1 day-0.39%
1 week+4.70%
Current month+4.70%
1 month+11.96%
3 months+0.66%
6 months-7.11%
Current year-4.41%
1 week 717
Extreme 717
767
1 month 643
Extreme 643
767
Current year 627
Extreme 627
976
1 year 627
Extreme 627
1,245
3 years 627
Extreme 627
3,225
5 years 627
Extreme 627
3,610
10 years 627
Extreme 627
3,610
Manager TitleAgeSince
Director of Finance/CFO - -
President 53 01/06/2016
Director TitleAgeSince
Director/Board Member 53 01/09/2013
Director/Board Member 81 01/06/2015
Director/Board Member 66 01/06/2020
Change 5-day change 1-year change 3-year change Capi.($)
-0.39%+4.70%-16.79%-75.15% 48.16M
+0.03%-0.35%+56.02%+50.58% 133B
-2.64%+4.85%+9.19%+39.42% 93.86B
-2.33%+3.34%+0.98%+72.50% 27.94B
-1.50%-3.47%+20.88%+49.20% 23.51B
+0.37%+2.50%-19.64%-24.29% 20.18B
-1.26%+7.71%+19.46%+148.53% 17.99B
-0.96%+1.88%+61.56%+124.05% 15.04B
-2.56%-3.08%-2.36%+6.97% 14.86B
-0.69%+4.76%-10.98%-2.76% 12.98B
Average -1.13%+4.95%+11.83%+38.91% 35.95B
Weighted average by Cap. -1.12%+4.40%+26.53%+49.30%

Financials

2026 2027 *
Net sales 2.87B 17.64M 15.48M 14.29M 13.2M 25.02M 1.69B 25.53M 172M 66.74M 827M 66.26M 64.81M 3.1B 19.06M 16.72M 15.43M 14.26M 27.03M 1.82B 27.57M 186M 72.09M 893M 71.57M 70M
Net income 180M 1.11M 971K 896K 828K 1.57M 106M 1.6M 10.77M 4.19M 51.85M 4.16M 4.06M 110M 676K 593K 548K 506K 959K 64.75M 978K 6.58M 2.56M 31.69M 2.54M 2.48M
Net Debt - -
Logo StemCell Institute Inc.
StemCell Institute Inc is mainly engaged in the cell bank business, which separates and stores cord blood. The Company operates cell bank business from umbilical cord blood and umbilical cord, development of new treatment methods and regenerative medicine products, regenerative medicine and fertility treatment, business development and investment in childbirth and childcare areas. The Company operates Cell Bank business segment. After signing the contract for the separation and storage of umbilical cord blood with customers (pregnant women), the umbilical cord blood collected at domestic umbilical cord blood collection cooperative hospitals (university hospitals, obstetric clinics and others) is collected, and carried into its cell processing center in Minato-ku, Tokyo and Midori-ku, Yokohama. It is stored at its cell storage center (Midori-ku, Yokohama, Kanagawa) for a long time at ultra-low temperature after stem cells contained in cord blood being separated, extracted and prepared.
Employees
117
Date Price Change Volume
08/07/26 ¥758.00 -0.39% 5,200
07/07/26 ¥761.00 +2.01% 5,900
06/07/26 ¥746.00 +0.67% 4,800
03/07/26 ¥741.00 +3.06% 15,900
02/07/26 ¥719.00 -0.55% 6,100

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 7096 Stock